journal article·2024-12Open access

AIP1 Regulates Ocular Angiogenesis Via NLRP12‐ASC‐Caspase‐8 Inflammasome‐Mediated Endothelial Pyroptosis

Yonghao Li, Yimeng Sun, Dasen Xie, Hui Chen, Qi Zhang, Shaochong Zhang, Feng Wen, Jing‐Song Ou, Min Zhang, Lishi Su, Xuri Li, Wei‐Ping Wen, Wei Chi

Advanced Science· Volume 11· Issue 47

Abstract

Abstract Pathological ocular angiogenesis is a significant cause of irreversible vision loss and blindness worldwide. Currently, most studies have focused on the angiogenesis factors in ocular vascular diseases, and very few endogenous anti‐angiogenic compounds have been found. Moreover, although inflammation is closely related to the predominant processes involved in angiogenesis, the mechanisms by which inflammation regulates pathological ocular angiogenesis remain obscure. In this study, a vascular endothelial cells (VECs)‐specific anti‐angiogenic factor is identified, apoptosis signal‐regulating kinase 1(ASK1)‐interacting protein‐1 (AIP1) as a key pathogenic regulator in a typical ocular angiogenesis model, oxygen‐induced retinopathy (OIR), using single‐cell RNA sequencing. It is demonstrated that AIP1 inhibited pathological angiogenesis by preventing a particular inflammatory death pathway, namely pyroptosis, in retinal VECs. The assembly of a noncanonical inflammasome is further uncovered, the NLRP12–ASC‐caspase‐8 inflammasome, which is promoted by decreased AIP1 in OIR. This inflammasome elicited gasdermin D (GSDMD)‐dependent endothelial pyroptosis, which in turn promoted the release of vascular endothelial growth factor (VEGF) and interleukin (IL)‐1β. Suppression of NLRP12–CASP8–GSDMD axis and AIP1 upregulation reduced VEGF signaling, limiting new vessel formation. These findings reveal a previously uncharacterized inflammatory angiogenic process involving VECs pyroptosis‐inducing retinal neovascularization, paving the way for promising therapeutic avenues targeting angiogenesis via AIP1 or pyroptosis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Inflammasome and immune disorders · Heme Oxygenase-1 and Carbon Monoxide · interferon and immune responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shenzhen Eye Hospital Shenzhen Key Laboratory of Ophthalmology Jinan University Shenzhen Guangdong 518043 China

State Key Laboratory of Ophthalmology Zhongshan Ophthalmic Center Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science Guangdong Provincial Clinical Research Center for Ocular Diseases Sun Yat‐Sen University Guangzhou Guangdong 510060 China

Xiamen Key Laboratory of Ophthalmology Xiamen Eye Center and Eye Institute of Xiamen University Xiamen Fujian 361003 China

Division of Cardiac Surgery Cardiovascular Diseases Institute The First Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong 510080 China

National‐Guangdong Joint Engineering Laboratory for Diagnosis and Treatment of Vascular Diseases NHC key Laboratory of Assisted Circulation and Vascular Diseases (Sun Yat‐sen University) Key Laboratory of Assisted Circulation and Vascular Diseases Chinese Academy of Medical Sciences Guangzhou Guangdong 510080 China

Department of Otolaryngology the Sixth Affiliated Hospital of Sun Yat‐sen University Otorhinolaryngology Institute of Sun Yat‐sen University Guangzhou Guangdong 510655 China

Funding

Natural Science Foundation of Guangdong Province · Natural Science Foundation of Hunan Province · National Natural Science Foundation of China

References (57)

Show source-provided references
1. 10.1038/nrc362710.1038/nrc3627 ↗
2. 10.1038/nature0448210.1038/nature04482 ↗
3. 10.1084/jem.2016164510.1084/jem.20161645 ↗
4. 10.3389/fimmu.2019.0161810.3389/fimmu.2019.01618 ↗
5. 10.1073/pnas.140281911110.1073/pnas.1402819111 ↗
6. 10.3390/ijms2018441110.3390/ijms20184411 ↗
7. 10.1038/s41419-020-02985-x10.1038/s41419-020-02985-x ↗
8. 10.3389/fimmu.2019.0008510.3389/fimmu.2019.00085 ↗
9. 10.1016/j.preteyeres.2012.08.00410.1016/j.preteyeres.2012.08.004 ↗
10. 10.1126/science.aal237910.1126/science.aal2379 ↗
11. 10.3389/fcvm.2018.0003910.3389/fcvm.2018.00039 ↗
12. 10.1038/ncomms1569910.1038/ncomms15699 ↗
13. 10.1016/j.cmet.2016.03.00410.1016/j.cmet.2016.03.004 ↗
14. 10.1172/JCI3616810.1172/JCI36168 ↗
15. 10.1038/srep4112310.1038/srep41123 ↗
16. 10.1038/s41419-019-1309-710.1038/s41419-019-1309-7 ↗
17. 10.1016/j.lfs.2021.11909010.1016/j.lfs.2021.119090 ↗
18. 10.1016/0014-5793(95)00956-A10.1016/0014-5793(95)00956-A ↗
19. 10.1046/j.1523-1755.2000.00139.x10.1046/j.1523-1755.2000.00139.x ↗
20. 10.1023/A:101229152472310.1023/A:1012291524723 ↗
21. 10.15252/embj.20179832110.15252/embj.201798321 ↗
22. 10.3390/jcm401017210.3390/jcm4010172 ↗
23. 10.1016/j.immuni.2015.03.00610.1016/j.immuni.2015.03.006 ↗
24. 10.7554/eLife.4039610.7554/eLife.40396 ↗
25. 10.1016/j.immuni.2012.07.00610.1016/j.immuni.2012.07.006 ↗
26. Xu Q. · Invest. Ophthalmol. Vis. Sci. · 2001 · 42 · 789
27. Tual‐Chalot S. · J. Vis. Exp. · 2013 · 9
28. 10.3390/cells905121710.3390/cells9051217 ↗
29. 10.3389/fimmu.2020.58368710.3389/fimmu.2020.583687 ↗
30. 10.1007/s11883-015-0503-z10.1007/s11883-015-0503-z ↗
31. 10.1161/ATVBAHA.113.30122010.1161/ATVBAHA.113.301220 ↗
32. 10.1074/jbc.M109.06938510.1074/jbc.M109.069385 ↗
33. 10.1186/s13024-020-00372-w10.1186/s13024-020-00372-w ↗
34. 10.1016/j.jtos.2020.07.00110.1016/j.jtos.2020.07.001 ↗
35. 10.1073/pnas.132423511110.1073/pnas.1324235111 ↗
36. 10.1038/nature1436210.1038/nature14362 ↗
37. 10.1038/s41419-017-0257-310.1038/s41419-017-0257-3 ↗
38. 10.1111/jpi.1244910.1111/jpi.12449 ↗
39. 10.1007/s00281-008-0113-810.1007/s00281-008-0113-8 ↗
40. 10.1016/S0140-6736(17)31193-510.1016/S0140-6736(17)31193-5 ↗
41. 10.1001/jamaophthalmol.2017.082110.1001/jamaophthalmol.2017.0821 ↗
42. 10.1001/jamaophthalmol.2017.105510.1001/jamaophthalmol.2017.1055 ↗
43. 10.1242/jcs.16377410.1242/jcs.163774 ↗
44. 10.1084/jem.2007260210.1084/jem.20072602 ↗
45. 10.1084/jem.2009109710.1084/jem.20091097 ↗
46. 10.1161/ATVBAHA.113.30305310.1161/ATVBAHA.113.303053 ↗
47. 10.1016/j.exer.2018.07.00110.1016/j.exer.2018.07.001 ↗
48. 10.1186/s12964-022-00877-510.1186/s12964-022-00877-5 ↗
49. 10.1038/s41586-024-07314-210.1038/s41586-024-07314-2 ↗
50. 10.1016/S1357-2725(01)00026-710.1016/S1357-2725(01)00026-7 ↗
51. 10.1038/s41598-018-21198-z10.1038/s41598-018-21198-z ↗
52. 10.1172/JCI12276710.1172/JCI122767 ↗
53. 10.1186/s12974-019-1505-510.1186/s12974-019-1505-5 ↗
54. 10.1016/j.cell.2016.07.05410.1016/j.cell.2016.07.054 ↗
55. 10.1073/pnas.171787111510.1073/pnas.1717871115 ↗
56. Samuel W. · Mol. Vis. · 2017 · 23 · 60
57. 10.1161/CIRCULATIONAHA.118.03836210.1161/CIRCULATIONAHA.118.038362 ↗